Reviewed Mar 2026 | PubMed sources
Active Market
Spain is selected. The evidence comparison is still valid, but provider availability, legal positioning, and cost assumptions may still be staged for later rollout.

Semaglutide vs Ipamorelin: Head-to-Head Comparison

Semaglutide is an FDA-approved GLP-1 agonist for direct weight loss, while ipamorelin is a GH secretagogue that can improve body composition through increased growth hormone. Semaglutide produces dramatically more weight loss, but ipamorelin may support lean mass retention and recovery.

Approved Comparison Routing

Approved options in this comparison

A
Semaglutide

Semaglutide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities. Brand names in the current dataset: Ozempic, Wegovy, Rybelsus.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It does not replace checking current labeling, payer rules, or local prescribing conditions.

Want to discuss Semaglutide with a provider?

Semaglutide is currently modeled on this site as an approved treatment path. Use the provider matcher to narrow fit by state, insurance, budget, and urgency.

Join provider rollout

Semaglutide Next Steps

ES selected - using US-first conversion assets

Side-by-Side Comparison

DimensionSemaglutideIpamorelin
Evidence LevelPhase III trials, FDA-approvedPhase II trials; no FDA approval
FDA StatusFDA-approved (Ozempic/Wegovy)Not approved
MechanismGLP-1 receptor agonistGhrelin receptor agonist (GH secretagogue)
Weight Loss Efficacy15-17% body weight in clinical trialsIndirect; improved body composition via GH, not direct weight loss
Side EffectsGI effects, potential thyroid/pancreatitis concernsMinimal; clean side-effect profile
Muscle ImpactLean mass loss of 25-40% of total weight lostGH elevation may support lean mass
CostVery high (branded)Moderate (research peptide)
Evidence Level
Semaglutide
Phase III trials, FDA-approved
Ipamorelin
Phase II trials; no FDA approval
FDA Status
Semaglutide
FDA-approved (Ozempic/Wegovy)
Ipamorelin
Not approved
Mechanism
Semaglutide
GLP-1 receptor agonist
Ipamorelin
Ghrelin receptor agonist (GH secretagogue)
Weight Loss Efficacy
Semaglutide
15-17% body weight in clinical trials
Ipamorelin
Indirect; improved body composition via GH, not direct weight loss
Side Effects
Semaglutide
GI effects, potential thyroid/pancreatitis concerns
Ipamorelin
Minimal; clean side-effect profile
Muscle Impact
Semaglutide
Lean mass loss of 25-40% of total weight lost
Ipamorelin
GH elevation may support lean mass
Cost
Semaglutide
Very high (branded)
Ipamorelin
Moderate (research peptide)

Peptide Overviews

Semaglutide

AFDA Approved

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). One of the most studied peptide drugs in recent history.

Weight LossFDA Approved
View full Semaglutide profile →

Ipamorelin

BHuman Studies

Ipamorelin is a selective growth hormone secretagogue that stimulates growth hormone release from the pituitary gland without significantly affecting cortisol or prolactin levels.

Growth Hormone SecretagoguesNot Approved
View full Ipamorelin profile →

GLP-1 Support Essentials

Products that can support side-effect management, hydration, and protein intake.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Supplies for Both

Common research handling and preparation supplies for injectable peptide workflows.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Semaglutide vs Ipamorelin: FAQ